Abstract
Radionuclides are applied in oncology for diagnosis and therapy. The former demands gamma — emitting radionuclides for labeling specific substrates for localizing malignant tissue and for analyzing tumor metabolism in vivo. Here, positron emission tomography (PET) may register in vivo the metabolism, for example, of glucose, amino acids, and receptors and of potentially useful cytotoxic agents. The advantage of the positron emitting radionuclides of carbon, nitrogen and fluorine is the labeling of substrates without changing substrate specificity within the metabolic reaction chain; also, substrate concentration in situ may be quantified. With regard to therapy radionuclides that emit β-and α-particles or decay by electron capture with the Auger effect, are administered in ionic form or with tumor seeking substrates. Examples are radioiodine for treating thyroid malignancy and radiophosphorus for myelopoliferative diseases. Organically bound radionuclides are given as labeled ligands for specific receptors, such as meta-iodo-benzylguanidine (MIBG) for treating the catecholamine producing tumors phaeochromocytoma and neuroblastoma and labeled monoclonal antibodies for tumors specific receptors. Highly localized energy depositions come from Auger emitters such as125I and by the neutron capture therapy, where boron-10 in the tumor cell is exposed to thermal neutrons for initiating the B10 (n; α) Li7 reaction, especially for treating neuro- and glioblastoma and melanoma. Endogenous radiotherapy with radionuclides rely on the success of delivering a proper amount of energy into individual tumor cells with optimal protection of normal tissue. The inevitable heterogeneity of energy deposition events from such approaches demands careful dosimetric assessment for which the classical methods of dosimetry for percutaneous radiotherapy are not applicable.
References
Apelgot S, Coppey J, Gaudemers A, Grisvard J, Guille E, Sasaki I, Sissoeff I (1989) Similar lethal effect in mammalian cells for two radio-isotopes of copper with different decay schemes,64Cu and67Cu. Int J Radiat Biol 55:365–384
Barth RF, Soloway AH, Fairchild RG (1990a) Boron neutron capture therapy of cancer. Cancer Res 50:1061–1070
Barth RF, Soloway AH, Fairchild RG (1990b) Boron neutron capture therapy for cancer. Sci Am 10:68–73
Beierwaltes WH (1978) The treatment of thyreoid carcinoma with radioactive iodine. Semin Nucl Med 8:79
Booz J, Paretzke HG, Pomplun E, Olko P (1987) Auger electron cascades, charge potential and microdosimetry of I-125. Radiat Environ Biophys 26:151–162
Brown I (1986) High linear energy transfer endoradiotherapeutic drugs for malignant disease. Doctoral thesis, Cambridge School of Clinical Medicine
Burki HJ, Roots R, Feinendegen LE, Bond VP (1973) Inactivation of mammalian cells after disintegrations of 3-H or 125-I in cell DNA at −196° C. Int J Radiat Biol 24:363–375
Deshponde SV, DeNordo SJ, Kukis DL, Moi MK, McCall MJ, DeNordo GL, Meares CF (1990) Yttrium-90-labeled monoclonal antibody for therapy: labeling by a new macrocyclic bifunctional chelating agent. J Nucl Med 31:473–479
Feinendegen LE (1975) Biological damage from the Auger-effect, possible benefits. Radiat Environ Biophys 12:85–95
Feinendegen LE (1978) Biological damage from radioactive nuclei incorporated into DNA of cells; implications for radiation biology and radiation protection. Proceedings of the 6th Symposium on Microdosimetry (CEC, Bruxelles) EUR 6064 DE-EN-FR, pp 3–35
Gabel D, Coderre JA (1989) Neutroneneinfang-Therapie von Melanomen. Spektrum Wissenschaft 8:46–54
Goldenberg DM (1979) Future role of radiolabelled monoclonal antibodies in oncological diagnosis and therapy. Semin Nucl Med 19:332–339
Hall EJ (1973) Radiobiology for the radiologist. Harper & Row, Maryland
Harbert JC (1987) Nuclear medicine therapy. Thieme, New York
Hatanaka H, Amano K, Kanemitsu H, Ikeuchi I, Yoshizaki T (1986a) Boron uptake by human brain tumors and quality control of boron compounds. In: Hatanaka H (ed) Boron neutron capture therapy for tumors. Nishimura, Niigata, pp 77–106
Hatanaka H, Kamano S, Amano K, Hojo S, Sano K, Egawa S, Yasukochi H (1986b) Clinical experience of boron neutron capture therapy for gliomas — a comparison with conventional chemo-immuno-radiotherapy. In: Hatanaka H (ed) Boron neutron capture therapy for tumors. Nishimura, Niigata, pp 349–378
Ichihashi M, Nakanishi T, Mishima Y (1982) Specific killing effect of 10B-para-broronophenylalanine in thermal neutron capture therapy of malignant melanoma: in vitro radiobiological evaluation. J Invest Dermatol 78:215–218
Jacobson HG (1988) Positron emission tomography in oncology. J Am Med Assoc 259:2126–2130
Langen KJ, Roosen N, Kuwert T, Herzog H, Kiwit JCW, Rota-Kops E, Muzik O, Bock WJ, Feinendegen LE (1989) Early effects of intraarterial chemotherapy in patients with brain tumours studied with PET: preliminary results. Nucl Med Commun 10:779–790
Linz U, Stöcklin G (1985) Chemical and biological consequences of the radioactive decay of iodine-126 in plasmid DNA. Radiat Res 101:262–278
Lueders Ch, Kopec M, Morstin K, Schmitz Th, Feinendegen LE (1992) Die Radiosynoviorthese — Anwendung und Durchführung unter besonderer Berücksichtigung dosimetrischer Aspekte. Akt Rheumatol 17:74–81
Meyer G-J, Schober O (1991) Evaluation of brain tumors by PET. In: Diksic M, Reba RG (eds) Radiopharmaceutical and brain pathology studied with PET and SPECT. CRC, Boca Raton, pp 303–336
Mintun MA, Welch MJ, Siegel BA, Mathias CJ, Brodack JW, McGuire AH, Katzenellenbogen JA (1988) Breast cancer: PET imaging of estrogen receptors. Radiology 169:45–48
Mishima Y, Ichihashi M, Tsui M, Hatta S, Ueda M, Honda C, Suzuki T (1989) Treatment of malignant melanoma by single thermal neutron capture therapy with melanoma-seeking 10B-compound. Lancet 2:388–389
Morstin K, Kawecha B, Feinendegen LE (1985) Depth dose optimisation for neutron capture therapy. Proceedings of the 5th Symposium on Neutron Dosimetry (CEC, Luxembourg) EUR 9762, pp 1073–1085
Pomplun E (1987) Mikrodosimetrische Berechnungen der Energiedeposition und des Dosisgrenzwertes nach Zerfall von Radionukliden in biologischen Systemen. Universität Düsseldorf, Mathem Nat Fakultät
Scherer E (ed) (1989) Proceedings of the 3rd International Symposium on Neutron Capture Therapy, Strahlenther Onkol 165:65–258
Soloway AH, Hatanka H, Davis MA (1967) Penetration of brain and brain tumor: VII. Tumor-binding sulfhydryl boron compounds. J Med Chem 10:714–717
Tyler JL, Yamamoto YL, Diksic M, Théron J, Villemure JG, Worthington D, Evans AC, Feindel W (1986) Pharmakokinetics of superselective intra-arterial and intravenous11C-BCNU evaluated by PET. J Nucl Med 27:775–780
Wieland DM, Wu JI, Brown LE, MJangner TJ, Swanson DP, Beierwaltes WH (1980) Radiolabelled adrenergic neutron-blocking agents: adrenomedullary imaging with 131-I-iodobenzylguanidine. J Nucl Med 21:349–353
Author information
Authors and Affiliations
Additional information
The “Journal of Cancer Research and Clinical Oncology” publishes in loose succession “Editorials” and “Guest editorials” on current and/or controversial problems in experimental and clinical oncology. These contributions represent exclusively the personal opinion of the author The Editors
Rights and permissions
About this article
Cite this article
Feinendegen, L.E. Contributions of nuclear medicine to the therapy of malignant tumors. J Cancer Res Clin Oncol 119, 320–322 (1993). https://doi.org/10.1007/BF01208838
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01208838